• Home
• Contact Us
• English | Français

• Corporate
  • Corporate Profile
  • Management Team
  • Board of Directors
  • Charter
  • Mandate of the Audit Committee
  • Code of Ethics
  • Careers at ConjuChem
  • Contact Us
• Technology
  • Technology platforms
  • About DAC™
  • About PC-DAC™
  • DAC™ Animation
• Products
  • PC-DAC™:Exendin-4
  • PC-DAC™:Insulin
  • DAC™:HIV
• Partnering
• Investors
  • Company Overview
  • Challenges
  • Business of ConjuChem
  • Benefits of Technology
  • Shareholder Value
  • Financial Information
  • Press Releases
• Careers
• Glossary

Investors

• Company Overview
• Challenges
• Business of ConjuChem
• Benefits of Technology
• Shareholder Value
• Financial Information
• Press Releases

Press Releases

• ConjuChem Announces Fiscal 2008 Second Quarter Financial Results
• ConjuChem Announces Changes to the Board of Directors
• ConjuChem Announces Fiscal 2008 First Quarter Financial Results
• ConjuChem Initiates Phase II Study of PC-DAC™:Exendin-4
• ConjuChem Biotechnologies Announces Fiscal 2007 Year-End Financial Results
• Conjuchem Biotechnologies Inc. Completes $22 Million Bought Deal Financing
• ConjuChem Biotechnologies Inc. Announces $22 Million Bought Deal Financing
• ConjuChem Reports Final Results of PC-DAC™: Exendin-4 Phase I/II Multiple-Dose Study for Type 2 Diabetes Confirming Safety and Efficacy at Once-Weekly Dosing
• Conjuchem's Request For Patent Reexamination Is Granted By U.S. Patent & Trademark Office
• ConjuChem Biotechnologies Announces Fiscal 2007 Third Quarter Financial Results
• Conjuchem Appoints Vice President & General Counsel
• Conjuchem Biotechnologies Announces Filing Of Patent Reexamination Request In U.S. Patent & Trademark Office
• ConjuChem Biotechnologies Reports PC-DAC™: Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
• ConjuChem Biotechnologies Announces Fiscal 2007 Second Quarter Financial Results
• PC-DAC™:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
• ConjuChem Biotechnologies Announces Fiscal 2006 Year-End Financial Results
• CONJUCHEM BIOTECHNOLOGIES INC. COMPLETES $120.25 MILLION FINANCING
• CONJUCHEM BIOTECHNOLOGIES INC. ANNOUNCES FILING OF FINAL PROSPECTUS
• CONJUCHEM BIOTECHNOLOGIES INC. ANNOUNCES FINANCING
• New Study of PC-DAC™Exendin-4 for Type 2 Diabetes Confirms Excellent Tolerability, Efficacy, and Extended Duration of Activity
• ConjuChem Initiates Phase I/II Multiple-Dose Study of PC-DAC™:Exendin-4
• CONJUCHEM BIOTECHNOLOGIES ANNOUNCES FISCAL 2006 THIRD QUARTER FINANCIAL RESULTS
• Final Results of PC-DAC™:Exendin-4 Phase I/II Trial for Type 2 Diabetes Confirm Excellent Tolerability, Positive Efficacy, and Extended Duration of Activity - New Three-Week Study Also Announced -
• CONJUCHEM PROVIDES FINDINGS OF DAC™:GRF HIV LIPODYSTROPHY TRIAL INVESTIGATION
• ConjuChem Announces Clinical Hold of its DAC™:GRF Program in HIV Lipodystrophy
• Presentations of ConjuChem's Novel Growth Hormone Therapeutic Highlighted at the 88^th Annual Meeting Of The Endocrine Society
• ConjuChem Successfully Completes Patient Enrollment of its Phase II Trial of DAC™:GRF for Treatment of HIV Lipodystrophy
• ConjuChem Biotechnologies Inc. Announces Fiscal 2006 Second Quarter Financial Results for Conjuchem Inc.
• ConjuChem's PC- DAC™:Exendin-4 Presented at the American Diabetes Association Annual Meeting
• ConjuChem Announces New Executive Vice President, Research and Development
• CONJUCHEM COMPLETES CORPORATE REORGANIZATION
  ConjuChem Receives $6.4 million in Non-Dilutive Capital
• ConjuChem Completes $15.75 Million Financing
• ConjuChem Announces $15.75 Million Bought Deal of Common Shares
• Phase I/II Preliminary Results of PC-DAC™: Exendin-4 Trial for Type 2 Diabetes Demonstrate Excellent Tolerability and Positive Efficacy
• ConjuChem Announces Fiscal 2006 First Quarter Financial Results
• ConjuChem to Initiate Phase I/II Clinical Study of PC-DAC™: Exendin-4 for Type 2 Diabetes
• ConjuChem Announces Reorganization and Non-Dilutive Funding
• ConjuChem Announces Fiscal 2005 Year-End Financial Results
• ConjuChem's PC-DAC(TM):Exendin-4 Advancing into Human Clinical Testing For Type 2 Diabetes
• ConjuChem Announces New President and CEO
• ConjuChem Provides Clinical Update on DAC™:GLP-1 Program and PC-Dac™:Exendin-4
• ConjuChem Announces Fiscal 2005 Third Quarter Financial Results
• CONJUCHEM DEVELOPS NEW PLATFORM, PC-DAC™

© 1999-2007, ConjuChem, Inc. All rights reserved.